EC Number   |
Protein Variants |
Reference |
|---|
   3.1.26.13 | A128T |
the mutant strain is resistant to 2-hydroxyisoquinoline-1,3(2H,4H)-dione inhibitors in contrast to the wild-type |
715859 |
| 3.1.26.13 | A360I |
mutation in the connection domain, the mutation significantly contributes to zidovudine resistance |
716993 |
| 3.1.26.13 | A360I/V |
site-directed mutagenesis, a connection/RNase H domain mutant |
716995 |
| 3.1.26.13 | A360K |
naturally occuring mutation in HIV infection patients, the mutation increases zidovudine resistance and decreased reverse trancriptase template switching |
716993 |
| 3.1.26.13 | A360V |
mutation in the connection domain, the mutation significantly contributes to zidovudine resistance |
716993 |
| 3.1.26.13 | A360V |
naturally occuring mutant from clinical isolates, a connection/RNase H domain mutant that shows reduced RNase H activity |
716995 |
| 3.1.26.13 | A371V |
mutation in the connection domain |
716993 |
| 3.1.26.13 | A371V |
site-directed mutagenesis, a connection/RNase H domain mutant |
716995 |
| 3.1.26.13 | A371V |
the E312Q, G333E, G335D, V365I, A371V and A376S substitutions in RNase H subdomain of HIV-1 reverse transcriptase are present in 26% of subtype B, whereas the G335D and A371V substitutions are commonly observed in 69% and 75% of non-B HIV-1 isolates, respectively |
707178 |
| 3.1.26.13 | A376S |
mutation in the connection domain, the mutation significantly contributes to zidovudine resistance |
716993 |
